Trial Profile

Phase III trial of Travivo in patients with major depressive disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gepirone (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Sponsors Fabre-Kramer Pharmaceuticals

Most Recent Events

22 Mar 2016 New trial record
17 Mar 2016 According to Fabre-Kramer Pharmaceuticals media release, the Food and Drug Administration (FDA) Office of New Drugs (OND) granted its appeal pursuant to the agency's Formal Dispute Resolution (FDR) process.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com